Latest Capital Markets News

AUCyber Limited has announced a significant reshuffle of its leadership team, appointing Chris Wright as CEO and welcoming three new non-executive directors, signaling a strategic pivot for the cyber security firm.

Bell Financial Group has reported a robust FY2024 performance, with profit after tax rising 26.4% amid improving market conditions and record Funds Under Advice. The company’s strategic focus on technology and recurring revenue streams underpins its growth trajectory.

Bell Financial Group reported a robust 26.4% increase in profit after tax to $30.7 million for 2024, underpinned by strong performances across all divisions and a declared fully franked final dividend of 4.0 cents per share. The Group is actively pursuing growth through acquisitions and strategic account transfers, positioning itself for a cautiously optimistic 2025.

Sequoia Financial Group will release its half-year FY25 financial results on 27 February 2025, accompanied by an investor webinar hosted by its CEO and CFO.

Select Harvests Limited delivered a standout FY24 with a record almond crop and a significant NPAT turnaround, underpinned by strategic cost management and a successful $80 million capital raise. The company signals continued growth and operational improvements heading into FY25.

WAM Active has delivered a remarkable 32.5% investment portfolio growth in 2024, significantly outperforming key market indices and declaring a fully franked interim dividend of 3.0 cents per share.

Dexus reports a 13.9% decline in Adjusted Funds from Operations for HY25, alongside a reduced distribution payout, while maintaining a robust balance sheet and advancing sustainability initiatives.

Dexus has reported a statutory net profit of $10.3 million for the half-year ending December 2024, rebounding from a significant loss last year, while maintaining strong portfolio occupancy and confirming steady distributions.

HMC Capital Limited has reported a remarkable 680% increase in profit for the half-year ended 31 December 2024, driven by key acquisitions and expansion into digital infrastructure and private credit sectors. The company also announced a fully franked interim dividend, underscoring confidence in its growth trajectory.

Challenger Limited posted a robust first half of FY25, with normalised net profit after tax rising 12% to $225 million, underpinned by strong Life and Funds Management segments despite softer annuity sales. The company maintains a confident outlook for FY25, forecasting further profit growth.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.